CAMBRIDGE, UK and RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, October 28, 2022 – Biofidelity, a revolutionary genomic technology company, announced that new data from its breakthrough ASPYRE® technology will be presented in a scientific poster at the upcoming Association for Molecular Pathology 2022 Annual Meeting, Nov. 1-5, in Phoenix, Ariz.
The poster, “ASPYRE: Validation of a Simple, Fast and Robust Novel Method for Complex Genetic Analysis of Actionable NSCLC Variants in Tissue and Plasma,” will be presented on Friday, November 4, 2022, from 9:15-10:15 am.
The ASPYRE technology is used to create targeted, multi-gene biomarker panels that are ultra-sensitive, highly specific, and capable of returning results in as little as two days. Using the technology, Biofidelity has developed ASPYRE-Lung®, a cost effective, simple and rapid assay that enables detection of multiple genomic biomarkers for patients diagnosed with non-small cell lung cancer (NSCLC).
“ASPYRE makes genomic data more accessible and easier to interpret, helping to ensure that all patients, globally, have the information needed to receive the right treatment at the right time,” said Dr. Barnaby Balmforth, Biofidelity co-founder and CEO.
A recently published scientific paper describes the assay, including its ability to detect multiple gene fusions from RNA and to analyze DNA and RNA concurrently from a single patient sample. According to the authors, detecting these fusions faster and at a lower cost has the potential to revolutionize patient care and make precision medicine globally accessible to more people.
Come by Biofidelity Booth #813 to learn more about ASPYRE or contact BD@biofidelity.com to set up a meeting to discuss ASPYRE-Lung clinical testing or the opportunity to set up the ASPYRE-Lung assay for research use in your lab.
Biofidelity is a revolutionary genomic technology company dedicated to unleashing the potential of genomics to transform human health and the world we live in. The company’s adaptive platform technology removes the noise from genomic data, providing only the information needed to make decision making less complex, faster, and more accurate.
Founded in 2019, Biofidelity is a rapidly growing private company of scientists, engineers, physicians and commercial experts dedicated to making genomics globally accessible.
Biofidelity’s unique ‘Allele-Specific PYrophosphorolysis REaction’ (ASPYRE) is the enabling technology behind Simplified Molecular Profiling, making it possible to generate assays that accelerate the detection of actionable biomarkers. The ASPYRE technology is used to create targeted, multigene biomarker panels that are ultrasensitive, highly specific, and capable of returning results in as little as two days.
Cambridge, UK, 28 July 2021 – Biofidelity Ltd, the cancer diagnostics company, today announces the opening of its US headquarters in Research...
Biofidelity Ltd, the cancer diagnostics company, today announced the opening of its new headquarters as it continues its significant recruitment...